We use the BET inhibitor apabetalone, developed to treat CVD, as a tool compound to counter the activity of BET proteins in noninflammatory and inflammatory conditions in hepatocytes in vitro, in mice and in CAD patients. Here, DNER is linked to coronary artery disorder.